title: Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations.
abstract: Octreotide is a recently available, FDA-approved, long-acting analog of somatostatin. The efficacy and tolerability of octreotide were evaluated in a series of protocols in healthy volunteers to assess its suitability for use in clinical investigations involving short-term inhibition of endogenous hormone secretion. Prolonged (270 minutes) hyperglycemic clamps were used to assess octreotide-mediated suppression of glucose-stimulated endogenous insulin secretion. Compared with a saline-control infusion, octreotide (30 ng/kg/min) suppressed stimulated insulin (P < .0001) and C-peptide (P < .0001) concentrations to basal levels. During insulin-induced hypoglycemia (plasma glucose < 40 mg/dL), octreotide (30 ng/kg/min) effectively suppressed the secretion of glucagon (P < .05) and growth hormone (P < .0005). In islet cell clamp studies, octreotide (30 ng/kg/min) suppressed C-peptide (P < .001), glucagon (P < .01), and growth hormone concentrations to below basal (fasting) levels in all subjects. Subsequent infusion of exogenous insulin, glucagon, and growth hormone resulted in predictable and stable concentrations of each hormone during octreotide-mediated suppression of their endogenous secretion. Consistent with the long half-life of octreotide (approximately 90 minutes), the concentrations of all three hormones remained suppressed below basal levels throughout a 60-minute observation period following the termination of octreotide infusion. In separate high-dose octreotide infusion studies, octreotide (60 ng/kg/min) did not produce any apparent additional metabolic effects, but was associated with an unacceptable degree of gastrointestinal side effects.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of New Mexico School of Medicine, Albuquerque 87131.
authors.forename: A J
authors.initials: AJ
authors.lastname: Krentz
authors.forename: P J
authors.initials: PJ
authors.lastname: Boyle
authors.forename: L M
authors.initials: LM
authors.lastname: Macdonald
authors.forename: D S
authors.initials: DS
authors.lastname: Schade
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005934:Glucagon / Q000097:blood*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced; D007262:Infusions, Intravenous; D007328:Insulin / Q000009:adverse effects / Q000097:blood*; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D015282:Octreotide / Q000008:administration & dosage / Q000494:pharmacology*; D011863:Radioimmunoassay; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013006:Growth Hormone; D005934:Glucagon; D015282:Octreotide